Einarsdottir, Berglind O.
Karlsson, Joakim http://orcid.org/0000-0001-6332-4043
Söderberg, Elin M. V.
Lindberg, Mattias F.
Funck-Brentano, Elisa
Jespersen, Henrik
Brynjolfsson, Siggeir F. http://orcid.org/0000-0003-0451-5581
Olofsson Bagge, Roger
Carstam, Louise
Scobie, Martin
Koolmeister, Tobias
Wallner, Olof
Stierner, Ulrika
Berglund, Ulrika Warpman
Ny, Lars
Nilsson, Lisa M.
Larsson, Erik
Helleday, Thomas
Nilsson, Jonas A.
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse (na)
Cancerfonden (na, na)
Vetenskapsrådet (na, na, na)
IngaBritt och Arne Lundbergs Forskningsstiftelse (na)
Familjen Erling-Perssons Stiftelse (na)
Sahlgrenska Universitetssjukhuset (na)
Stiftelsen för Strategisk Forskning (na)
Article History
Received: 28 March 2018
Revised: 29 June 2018
Accepted: 5 July 2018
First Online: 24 July 2018
Change Date: 6 February 2020
Change Type: Correction
Change Details: On Pubmed, the name of co-author Roger Olofsson Bagge appeared incorrectly as “Bagge RO” instead of “Olofsson Bagge, Roger”. This has been corrected in the PDF and HTML versions.
Conflict of interest
: M.S., T.K., O.W., U.W.B., T.H., and J.A.N. are shareholders of Oxcia, which commercialize anti-cancer drug development projects, including MTH1 inhibitors from the Helleday Foundation. The remaining authors declare that they have no conflict of interest.